Regulatory T Cells in the tumor microenvironment and cancer progression: role and therapeutic targeting.
Name:
vaccines-04-00028-v2.pdf
Size:
525.2Kb
Format:
PDF
Description:
Open access full text article
Affiliation
Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.Issue Date
2016
Metadata
Show full item recordAbstract
Recent years have seen significant efforts in understanding and modulating the immune response in cancer. In this context, immunosuppressive cells, including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), have come under intense investigation for their proposed roles in suppressing tumor-specific immune responses and establishing an immunosuppressive tumor microenvironment, thus enabling tumor immune evasion. Additionally, recent evidence indicates that Tregs comprise diverse and heterogeneous subsets; phenotypically and functionally distinct subsets of tumor-infiltrating Tregs could contribute differently to cancer prognosis and clinical outcomes. Understanding Treg biology in the setting of cancer, and specifically the tumor microenvironment, is important for designing effective cancer therapies. In this review, we critically examine the role of Tregs in the tumor microenvironment and in cancer progression focusing on human studies. We also discuss the impact of current therapeutic modalities on Treg biology and the therapeutic opportunities for targeting Tregs to enhance anti-tumor immune responses and clinical benefits.Citation
Regulatory T Cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. 2016, 4 (3): Vaccines (Basel)Journal
VaccinesDOI
10.3390/vaccines4030028PubMed ID
27509527Type
ArticleLanguage
enISSN
2076-393Xae974a485f413a2113503eed53cd6c53
10.3390/vaccines4030028
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Related articles
- Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer.
- Authors: Chaudhary B, Abd Al Samid M, al-Ramadi BK, Elkord E
- Issue date: 2014 Jul
- Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
- Authors: Sasidharan Nair V, Elkord E
- Issue date: 2018 Jan
- Expression of costimulatory and inhibitory receptors in FoxP3(+) regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches.
- Authors: Toker A, Ohashi PS
- Issue date: 2019
- Treg-mediated acquired resistance to immune checkpoint inhibitors.
- Authors: Saleh R, Elkord E
- Issue date: 2019 Aug 10
- TNFR2: Role in Cancer Immunology and Immunotherapy.
- Authors: Yang Y, Islam MS, Hu Y, Chen X
- Issue date: 2021